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1. Introduction
Neoadjuvant chemotherapy (NAC), also referred to as preoperative or primary chemotherapy
refers to chemotherapy administered prior to tumor resection. It is a standard of care for
management of locally advanced or inoperable breast tumors.
2. Rationale for NAC
The clinical rationale of NAC administration lies in the fact that it significantly downstages
the existing tumor, enabling greater breast conservation (BSC). Although preoperative
chemotherapy has not been shown to improve disease free (DFS) and overall survival (OS) for
breast cancer when compared to post-operative therapy in operable patients, achievement of
pathological complete response (pCR) defined as absence of any residual invasive tumor, is
an important predictor of superior DFS and OS. In the B-27 trial looking at addition of taxanes
to anthracycline based regimen in NAC, after 8 years of follow, patients who achieved pCR
had superior DFS (HR: 0.49, p<0.0001) and OS (HR: 0.36, P<0.0001) rates. [1]- [5] The more
recent I-SPY 1 study amongst several other studies [6]- [8], have found pCR to be an important
predictor of recurrence free survival. [9], [10]
NSABP B-18 study was one of the earliest trials comparing neoadjuvant to adjuvant chemo‐
therapy. The regimen of choice in this trial was the combination of adriamycin and cyclo‐
phosphamide (AC) either pre- or post operatively in 1523 women with operable palpable (T1-3,
N0-1, M0) newly diagnosed breast cancer. There was no difference in overall survival between
the two groups. However, a significantly greater number of patients underwent BCS in the
NAC group (67vs. 60%, p=0.002).
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In another trial of 1355 women with operable breast cancer, doxorubicin and paclitaxel
followed by CMF in the neoadjuvant setting yielded similar RFS and OS rates when compared
to adjuvant chemotherapy. However, patients with neoadjuvant chemotherapy achieved
much higher breast conservation rates (63% vs. 34%, p<0.001). Distant relapse free survival
was inferior in patients who did not achieve pCR (HR, 0.43; p- 0.025). [11]
3. Prognostic factors
Clinical trials have described various clinical and histological features of breast tumors, which
may predict response to neoadjuvant chemotherapy. Higher nuclear grade is a significant
predictor of pCR with NAC in several studies. [12]- [17] Proliferation index or Ki-67 [18] is
shown to correlate positively to response. In the I SPY 1 trial, pCR rates in patients with high
Ki-67 (defined as >20 percent) were 35% vs. 5% in patients with low Ki-67 (defined as <10
percent). [19] [9], [20] Pathologic examination of 82 breast cancer tumors after NAC with
paclitaxel followed by 5-fluorouracil, adriyamicin and cyclophosphamide (T฀ FAC) showed
that basal like tumor pathology was a predictor of good response to NAC. [21] In the I SPY 1
trial luminal A histology had lowest pCR rates. [8], [19], [22] Negative estrogen and proges‐
terone receptor status has shown to predict better response to NAC [7], [8], [13], [18], [23] In
the I-SPY 1 trial pCR was highest for hormone receptor negative and HER-2 positive cancer
(54%) and lowest for HR+/ Her-2 negative cancer (9%). [19], [24] In a study of 388 patients in
which 16 percent patients were Her-2 positive, Her-2 positivity and young age were important
predictors of achievement of pCR with anthracycline based NAC in univariate analysis. [25]
There is no single genetic marker that predicts complete response to NAC. However, gene
expression profiling has been studied to predict response to various chemotherapy regimens
with reasonable accuracy. [26] [27], [28] van’t Veer et al developed a 70-gene expression model
for prognostication using microarray analyses on 117 breast tumors. They found that genes
associated with poor prognosis regulated cell cycle, metastasis, invasion and angiogenesis (eg.
cyclin E2, MCM6, metalloproteinases MMP 9, MP1, RAB6B, PK428, VEGF receptor FLT1). [29]
In the I SPY 1 trial, patients with p-53 null mutations and 17q amplification were also associated
with high pCR rates (47% and 45% respectively). [19]
Enzymes of cytochrome P450 family play an important role in cancer drug metabolisms and
polymorphism CYP2C9*2 polymorphism has been found to be associated with NAC resist‐
ance. [30] Tumor stage, lymph node positivity and dose intensity of chemotherapy have not
been found to correlate to NAC response. [31] [17], [32]
Apoptotic responses to first dose of NAC measured by serial fine needle aspirations dur‐
ing first  4 days after chemotherapy administration was also found to be an indicator of
response.  [33].  Persistently  elevated levels  of  CXCR4,  a  G-protein coupled receptor  post
chemotherapy has been found to be a negative predictor for response. [34]. A retrospec‐
tive study of 562 patients concluded that metaplastic,  mucinous and apocrine carcinoma
responded poorly to NAC. [35]
Neoadjuvant Chemotherapy - Increasing Relevance in Cancer Management64
4. Chemotherapy regimens
In the pre-taxane era, initial trials of NAC were performed with anthracycline based regimens,
such as AC [3]; 5-Fluorouracil, Adriyamicin and Cyclophosphamide (FAC)36 and 5-Fluorour‐
acil, Epirubicin, Cyclophosphamide (FEC). [37] However, more recent trials have demonstrat‐
ed that taxanes, when added to anthracycline based regimens, significantly improve survival
outcomes [38] and therefore, should be used in combination with anthracycline based
regimens. NSABP B-27 trial was designed to observe the impact of addition of 4 cycles of
docetaxel to standard AC regimen in the preoperative setting. 2411 patients with T1C-3N0M0
or T1-3N1M0 breast tumors were assigned to ACX4 cycles vs. ACX 4 cycles followed by
docetaxel X4 cycles vs. AC X 4 cycles preoperatively and docetaxel X 4 cycles postoperatively.
Although the trial did not meet it’s primary end point of demonstrating survival benefit,
addition of docetaxel did double the pCR rates (from 13% to 26%). pCR rates were also
significant predictor of improved DFS (HR: 0.49) and OS (HR: 0.36) after more than eight years
of follow-up. Patients who achieved clinical partial response with AC had significantly
increased DFS with addition of docetaxel [39]
For patients with the Her-2 positive cancer, trastuzumab has been incorporated in the initial
neoadjuvant chemoregimens. Options include sequential trastuzumab and paclitaxel and FEC
in combination with trastuzumab (PH- FECH) with pCR rates ranging from 55-65 percent. [40]
However, in patients where cardiac morbidity is a concern docetaxel and cyclophosphamide
in combination with trastuzumab (TCH) is also an effective choice. [41]
Capecitabine is an effective drug, which has yielded promising results in metastatic breast
cancer. Capecitabine in combination of Vinorelbine has been found to be non inferior to
Docetaxel, Adriyamicin, Cyclophosphamide (TAC) in terms of sonographic and pathologic
complete response and breast conservation rates in the phase 3 Gepar trio trial [42]
5. Dose dense NAC
Dose intensity is achieved by increasing the drug dose delivered per cycle of chemotherapy
by either increasing dose or decreasing inter-treatment interval. The PREPARE trial used dose
dense (dd) and dose intensified regimens of E+ P followed by CMF and compared it with
standard dose EC→T regimen. Patients were treated with E (dd) → T (250mg/m2)(dd) → CMF,
each 2 weekly for 3 cycles with or without darbopoeitin versus standard E (90mg/m2) and C
followed by P (150mg/m2) for four cycles (EC→T). The pCR rate was higher in the dose-dense,
dose-intensified group (18.7% vs. 13.2%; p=0.04). Patients with non-inflammatory breast cancer
had significantly improved disease free and overall survival from the dose dense regimens.
[43]. A few other trials demonstrate similar increased in pCR rates with dose dense chemo‐
therapy. [44] Currently, the value of dose dense chemotherapy in breast cancer is unclear
amongst unselected patients.
In a phase 3 trial (SWOG 0012), standard 3 weekly AC regimen was compared to week‐
ly doxorubicin and daily oral cyclophosphamide with GCSF support in the neoadjuvant
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setting  for  inflammatory  and  locally  advanced  breast  cancer.  pCR  rates  with  the  dose
dense regimen were superior only in stage IIIB breast cancer and IBC. There was no dif‐
ference in DFS and OS. [44]
6. Assessment of response after NAC: Definition of pCR
In most studies, pCR has been defined as absence of any residual invasive tumor in the
pathologically examined tissue. Prior studies have indicated that there is no survival dif‐
ference in  patients  with no residual  tumor (in-situ or  invasive)  versus patients  with re‐
sidual in-situ (non- invasive tumor) cancer.  [45] In a study performed at MD Anderson,
2302 patients treated with NAC showed similar disease free, overall and local recurrence
free survival for patients who had in-situ cancer at the end of treatment when compared
to patients who had no residual cancer. [46] However a recently published pooled analy‐
sis  of  6,377  patients  trials  shows that  DFS  is  better  in  patients  with  no  residual  tumor
when  compared  to  patients  with  residual  in-situ  tumor  (HR:1.74,  95%  CI  1.28-2.36,
p<0.001).  This study concluded that definition pCR should strictly be limited to absence
of residual invasive or in-situ tumor either in the breast or lymph nodes [47].
7. Estrogen or progesterone receptor positive cancer
Although the use of endocrine therapy in the adjuvant setting is very common, it’s use in the
neoadjuvant setting is relatively recent. Neoadjuvant endocrine therapy has shown to cause
tumor shrinkage [48] and reduce tumor proliferation as evidenced by decrease in Ki-67 and
other markers of proliferation. [49] pCR is less commonly observed, therefore, response
assessment in most of the trials involving endocine therapies is clinical (palpation and
radiological techniques) as well as pathological assessment of proliferation markers. [50]
Comparisons have also been made between the 3 aromatase inhibitors exemestane, letrozole
or anastrozole, in the neoadjuvant setting. 377 postmenopausal women with stage II/III ER
positive breast cancer were treated with neoadjuvant exemestane (25mg/d), letrozole
2.5mg/d and anastrozole 1mg/d for 16-18 weeks. Clinical response rate, which was the primary
end point of the trial, was 62.9%, 74.8% and 69.1% respectively. Breast conservation rates were
comparable amongst the three groups. No difference was observed in terms of Ki-67 levels or
changes in KI-67 expression among all the groups suggesting that they have biological
equivalent effects. Overall, Luminal A tumors were likely to have a preoperative endocrine
operative index (PEPI) score of zero before surgery when compared to luminal B tumors. [51]
Combination of neoadjuvant hormone and chemotherapy is also being investigated. In a phase
3 trial of 101 post menopausal women with locally advanced hormone receptor positive breast
(stage T3, T4 and/ or N2 N3) cancer, neoadjuvant chemotherapy with FAC combined with
letrozole 2.5mg daily produced superior pCR (25.5% VS. 10.2%, p=0.049) and clinical complete
response rates (27.6% VS. 10.2%, P=0.037) when compared to FAC alone. [52]
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It has been postulated that phosphotidyl kinase 3/ AKT/ mTOR pathway may be involved in
endocrine resistance. For this reason, mTOR inhibitor like everolimus have been combined
with hormone therapy in clinical trials. In a phase 2 trial comprising of 270 untreated patients
with ER positive breast cancer, the control group was treated with letrozole (2.5mg/day) +
placebo while the experimental treatment group was treated with letrozole plus everolimus
(10mg/day). Patients treated with letrozole plus mTOR (mammalian target of Rapamycin)
inhibitor had significantly improved clinical response rates, as well as response rates as
assessed by ultrasound and mammography. Decrease in the proliferation index Ki-67 was
significantly more marked with the combination treatment. Toxicities with the combination
group were higher with 52.9% patients in the combination group having treatment stopped
or delayed as a result of toxicities (only 7.6% in the placebo group). It was inferred that mTOR
inhibitor can significantly increase the efficacy of hormone therapy. [53]
8. HER-2 receptor positive cancer
Trastuzumab or herceptin (H), a monoclonal antibody against HER-2 neu receptor, is an
integral part of neoadjuvant chemotherapy in HER-2 positive tumors. In a phase 3 trial, FEC
+ Trastuzumab followed by P + trastuzumab has shown significantly higher pCR rates when
compared to FEC→ P alone (66.7% vs. 25%). [54]
In the NeOAdjuvant herceptin (NOAH) trial, patients with HER-2 positive inflammatory or
locally advanced breast cancer were treated with neoadjuvant chemotherapy alone (A+P →
P→ CMF) or neoadjuvant chemotherapy combined with neoadjuvant H (added to the CMF
part of neoadjuvant chemotherapy). Addition of H not only improved the rates of pathological
response, (50% vs. 26%; p=0.002) but also the rates of event free survival, which was the primary
end point of the study. More patients were able to undergo breast conservation surgery with
the addition of H (35 vs. 13% p=0.07). [55]
Trastuzumab has been compared to lapatinib (L), a tyrosine kinase inhibitor which is a dual
inhibitor of EGFR and Her-2 receptors, in the neoadjuvant setting. In the Gepar Quinto trial,
patients were treated with standard chemotherapy with four cycles of Epirubicin and cyclo‐
phosphamide followed by four cycles of docetaxel along with either H (6mg/kg every 3 weeks)
or L (1250mg daily) starting on the day 1 of the first EC cycle till the day 21 of the fourth cycle
of docetaxel. pCR rates with H were significantly higher (30%) when compared to L (30% vs.
22%; p=0.04). Overall difference in the clinical response and the number of breast conservation
surgeries between the two groups was not significant. Edema and dyspnea were more common
with trastuzumab while rash and diarrhea were more common with lapatinib. [56]
Neo-Altto trial was a randomized phase 3 trial comparing dual (trastuzumab/lapatinib
combination) versus single Her-2 receptor blockade (trastuzumab or lapatinib alone) for
HER-2 positive breast cancer, >2cm in diameter along with a taxane in the neoadjuvant setting.
154 patients received 1500mg of PO lapatinib, 149 received 4mg IV trastuzumab (2mg/kg
subsequent doses) and 152 received the combination of trastuzumab with 1000mg PO
lapatinib. pCR rates were significantly higher with dual blockade (51.3 percent; 95% C.I.
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43.1-59.5%) when compared to single blockade with trastuzumab alone (29.5%; 95% C.I.
22.4-37.5). No significant difference in the pCR rates between trastuzumab and lapatinib
groups was observed (p=0.34). Grade 3 diarrhea and elevation of liver enzymes were more
common side effects in the lapatinib (23.4%) and lapatinib plus trastuzumab group (21.1%)
when compared to trastuzumab only group (2%). The rate of breast conservation surgery in
all the three groups was similar. pCR rate was higher in the ER negative tumors. [57]
In the preliminary results of the NSABP B-41 trial presented in American Society of Clinical
Oncology’s (ASCO) annual meeting in 2012, when H is substituted with L, the responses pCR
rates are found to be comparable. This trial comparing AC→ weekly paclitaxel (WP)+ H vs.
AC→ WP + L vs. AC→ WP+ H+L; showed that pCR rates with H and L were comparable (52.5%
for T vs. 53.2% for L). pCR rates with the combination of both T and L with NAC was slightly
higher but the results were not statistically significant (62% p= 0.075). [58]
Trastuzumab has been combined with another humanized monoclonal antibody against
HER-2, Pertuzumab, which binds the dimerization site of HER-2 receptor and inhibits ligand
dependent signaling. The phase 2 multicenter Neosphere trial compared combinations of H+
T (group A), H+ Pertuzumab +T (group B), Pertuzumab +H (group C) and pertuzumab + T
(group D) as neoadjuvant treatment of Her-2 positive breast cancer. The pCR rates in group B
was significantly higher (45.8%, p=0.0141) when compared to groups A, C or D (29%, 16.8%
and 24 % respectively). Clinical responses to NAC were also highest in group B. The rate of
febrile neutropenia was similar in the trastuzumab+ pertuzumab + chemotherapy group to the
H+ T group and was 7-8%. [59]
Trastuzumab combined with bevacizumab and chemotherapy was found to be very effective
in Her-2 positive inflammatory breast cancer in the phase 2 BEVERLY-2 trial. In this study, 52
patients were treated with FEC + Bevacizumab (cycles 1-4) and docetaxel +bevacizumab and
trastuzumab (cycles 5-8). pCR was seen in 33 patients (63.5%). The frequency of grade ¾
neutropenia was 48%. [60]
9. Role of bevacizumab
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF),
which has been found to be very effective when added to anthracycline- taxane based
neoadjuvant therapy. In the phase 3 NSABP- 40 trial, [61] patients with T1c-T3/ N0-N2 were
treated with the following regimens: Docetaxel (T) alone followed by EC vs. T + Gemcitabine
followed by EC vs. T + G + Bevacizumab followed by EC vs. T + Capecitabine (X) followed by
EC vs. T + X + Bevacizumab followed by EC. Addition of bevacizumab significantly increased
the pCR rates in the breast, which was the primary end point of this study (28.2% to 34.5%,
p=0.02). pCR rate in breast and nodes (secondary end point) was also increased but the result
was not significant. Rate of clinical complete responses was significantly increased with
addition of bevacizumab. Effect of bevacizumab was more pronounced in hormone receptor
positive tumor and higher tumor grade. Side effects observed with bevacizumab included
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significantly higher rates of hypertension, left ventricular systolic dysfunction, mucositis and
hand-foot syndrome.
Another phase 3 trial (GEPAR QUITNO) consisting if 1948 HER-2 negative patients concluded
that rates of pCR were significantly improved when bevacizumab was added to EC→ T
regimen (14.9% with EC→T alone and 18.4% with EC→ T+ Bevacizumab). In this study,
improvement in pCR was limited to patients with hormone receptor negative tumor (39 with
bevicizumab VS. 28% without bevacizumab). Side effect profile of bevacizumab was similar
to the abovementioned study. [62]
Findings of the above two studies have led to conflicting results. While former has shown
benefit of bevacizumab in hormone receptor positive patients, the latter has shown benefit in
hormone negative cancer. A phase 3 ARTemis trial is currently underway which compares
addition of bevacizumab to standard chemotherapy to chemotherapy alone. The study is to
finish recruitment in December 2012 and primary outcome analysis due by December 2013. [63]
However, in some other trials, addition of bevacizumab to chemotherapy has shown less
efficacy with additional toxicity. In one study, 45 women with Her2 negative locally advanced
breast cancer were treated with neoadjuvant AC + bevacizumab X4 cycles followed by TX+
bevacizumab X4 cycles, with pCR rates of only 9 percent with substantial added toxicity such
as fatigue, mucositis and headache. [64]
Trials looking at pathological markers predicting response to bevacizumab have shown posi‐
tive responses associated with negative hormone receptor status, high Ki67 index and changes
in phosphorilation status of VEGF receptor 2 (
J Clin Oncol 30, 2012 (suppl; abstr 10595))
10. NAC in triple negative breast cancer
Triple negative breast cancer is a more aggressive form of breast cancer that has poor prognosis
despite response to chemotherapy. TNBC has been found to be sensitive to platinum based
treatment in the metastatic setting due to inherent genomic instability. Encouraged by success
in the metastatic setting, trials have been conducted with platinum agents in the primary
setting. Silver et al. treated 28 patients with stage II/III TNBC with four three weekly cycles of
cisplatin. pCR was seen in 22% patients; good pathological response (Miller Payne score of 3,4
or 5) in 50% and progression in 14% patients. Positive response to cisplatin in this study was
associated with young age, low BRCA expression, BRCA-1 prominent methylation, p-53
frameshift or nonsense mutation and gene expression significant of E2F3 activation. [65] More
pCR rates have been demonstrated in BRCA-1 mutated breast cancers with cisplatin than with
conventional regimens such as AC or CMF. [66] In another study, 17 patients with triple
negative breast cancers >2cm in size, were treated with weekly doxorubicin plus daily oral
cyclphosphamide followed by weekly paclitaxel and carboplatin, 14 out of 15 assessable
patients showed clinical response. pCR rate was 46.6%. Seven patients had grade ¾ hemato‐
logical toxicity with this combination. [67] Similar high pCR rates have been reported with
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neoadjuvant bevacizumab, docetaxel and Carboplatin combination. [68] However, in a
multicenter phase 2 study, addition of carboplatin to standard EC→T regimen for basal like
breast cancer (defined as ER-/PR-/Her2-/Cytokeratin 5/6+ and /or EGFR+) did not enhance
efficacy of standard chemotherapy (pCR rates: 35% vs. 30% in Carboplatin vs. no Carboplatin
group, p=0.6064). [69]
The phase 3 GeparQuinto study demonstrated that addition of Bevacizumab to conventional
chemotherapy (EC→ T) can further improve pathological CR (pCR) rates in triple negative
breast cancer. [62]. However, as mentioned above, these findings contradict with the NSABP
B40 study where major benefit was obtained in hormone positive cancer. [70] Carboplatin in
combination with weekly nab paclitaxel and bevacizumab is also currently being evaluated in
a clinical study. [71]
Ixabepilone  is  a  new  class  of  semisynthetic  microtubule  inhibiting  drugs  which  is  de‐
rived from natural  epithilones.  It  has  shown promising results  in  metastatic  and multi‐
drug resistant (anthracyclines, capecitabine, taxanes) breast cancer. [72]- [76] In a phase 2
study designed to  assess  benefit  of  ixabepilone  in  the  neoadjuvant  setting,  161  patients
were  treated with  four  cycles  of  ixabepilone.  pCR was observed in  18% in  all  patients,
but  in  29%  of  ER  negative  patients,  ER  gene  expression  was  inversely  related  to  re‐
sponse in this study. [77] A pooled analysis of data from five phase 2 and two phase 3
trials, pCR rates with ixabepilone in the neoadjuvant setting were 26% in TNBC vs. 15%
in non TNBC. [77], [78] Newer non-taxane microtubule inhibiting agents such as eribulin
are being evaluated as NAC for TNBC in clinical trials.
Poly ADP ribose polymerase (PARP) inhibitors inhibit the PARP-1 enzyme which is a DNA
base excision repair enzyme and along with BRCA, is involved in cell’s DNA repair. [79], [80]
It’s role in tumorigenesis in evidenced by it’s upregulation seen in tumor cells, thus protecting
cancer cell DNA from damage and cell death. [81] PARP inhibition leads to cell death by two
mechanisms. First, it causes accumulation of single and double stranded DNA breaks causing
subsequent cell death. Secondly, it causes sensitization to therapeutic DNA damage. [82] Two
trials utilizing PARP inhibitor Iniparib in combination of preoperative setting are underway
and results are expected soon.
11. Role of neoadjuvant chemoradiation
In a multi-institutional study, 105 patients with locally advanced breast cancer were treated
with twice weekly paclitaxel 30mg/m2 for 10-12 weeks and radiation therapy (total 45gy) over
weeks 2-7. Trastuzumab was added to this regimen in patients found to be Her-2 positive.
Pathological response (complete and partial) was achieved in 34% patients and was found to
be significantly higher in hormone receptor negative patients (54%, 95% C.I. 36%-69%) and
triple negative tumors (54%). As expected, patients who achieved pathological response had
higher disease free survival (57 months vs. not reached, HR: 2.85, p<0.001) and overall survival
(84 months vs. not reached, HR: 4.27). [83]
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12. Monitoring response to NAC
Assessment of radiological response especially when using MRI or PET scan is very useful
since it may help in early differentiation of responders to NAC from non-responders.
Studies  have  shown  that  decrease  in  tumor  volume  and  enhancement  on  contrast  en‐
hanced  MRI  is  associated  with  major  histopathological  response.  [84],  [85]  Loo  et  al
showed that  MRI was able  to  monitor  response to  NAC more accurately in  TNBC and
Her-2  positive  subsets  but  not  in  ER+,  Her-2  negative  subsets.  [86]  The  I-SPY-1  study
found that  decrease  in  tumor  volume as  assessed  by  MRI  early  during  treatment  with
NAC was a better predictor of pathologic response than measurement of tumor diameter
by physical examination alone.
PET CT is another valuable imaging modality for accurately predicting response to NAC
early in the course if therapy. [87], [88] In a study of 33 patients treated with carboplatin
based NAC, there was significant correlation between FDG PET metabolic response after
first and third cycles and overall survival. [89]
Studies have compared MRI and PET scan as predictors of response to NAC. Choi et al
found that compared to PET CT, MRI was highly predictive of pCR (P<0.005) and better
than PET CT for monitoring response to NAC. [90] However, Rousseau et al found that us‐
ing 60% cut off value for SUV, the sensitivity, specificity and negative predictive value of
PET scan were 89%, 955 and 85% respectively after two cycles of NAC. Values were much
lower for US and mammography. Tateishi et al also found PET CT to be superior to DCE
MRI for pCR prediction after 2 cycles of NAC. [91]
13. Conclusion
NAC is the standard of care in management of locally advanced and inoperable breast can‐
cer. It significantly downstages the tumor, thereby permitting breast conservation surgery.
Anthracycline and taxanes based regimens are most commonly used NAC regimens. For
Her-2 positive tumors, trastuzumab should be included in the NAC regimen. Role of other
targeted therapies in NAC is being investigated.
Author details
Jasmeet Chadha  Singh and Amy  Tiersten
New York University Medical Center, New York, NY, USA, USA
Neoadjuvant Chemotherapy: Role in Breast Cancer
http://dx.doi.org/10.5772/53192
71
References
[1] Chollet P, Amat S, Cure H, et al: Prognostic significance of a complete pathological
response after induction chemotherapy in operable breast cancer. Br J Cancer
86:1041-6, 2002
[2] Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: updates of Na‐
tional Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin On‐
col 26:778-85, 2008
[3] Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with
operable breast cancer: nine-year results from National Surgical Adjuvant Breast and
Bowel Project B-18. J Natl Cancer Inst Monogr:96-102, 2001
[4] Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative doce‐
taxel added to preoperative doxorubicin plus cyclophosphamide for operable breast
cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin On‐
col 24:2019-27, 2006
[5] Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients
with complete pathologic primary tumor and axillary lymph node response to dox‐
orubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-9, 1999
[6] Zhang GC, Qian XK, Guo ZB, et al: Pre-treatment hormonal receptor status and Ki67
index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but
not disease-free survival in HER2-positive breast cancer patients. Med Oncol, 2012
[7] Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-
term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-81,
2008
[8] Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: primary tumor che‐
mosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-34, 2007
[9] Esserman LJ, Berry DA, Demichele A, et al: Pathologic Complete Response Predicts
Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY
1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol, 2012
[10] Untch M, Fasching PA, Konecny GE, et al: Pathologic complete response after neoad‐
juvant chemotherapy plus trastuzumab predicts favorable survival in human epider‐
mal growth factor receptor 2-overexpressing breast cancer: results from the
TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351-7, 2011
[11] Gianni L, Baselga J, Eiermann W, et al: Phase III trial evaluating the addition of pacli‐
taxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil,
as adjuvant or primary systemic therapy: European Cooperative Trial in Operable
Breast Cancer. J Clin Oncol 27:2474-81, 2009
Neoadjuvant Chemotherapy - Increasing Relevance in Cancer Management72
[12] Andre F, Mazouni C, Liedtke C, et al: HER2 expression and efficacy of preoperative
paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108:183-90,
2008
[13] Osako T, Horii R, Matsuura M, et al: High-grade breast cancers include both highly
sensitive and highly resistant subsets to cytotoxic chemotherapy. J Cancer Res Clin
Oncol 136:1431-8, 2010
[14] Fisher ER, Wang J, Bryant J, et al: Pathobiology of preoperative chemotherapy: find‐
ings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Cancer 95:681-95, 2002
[15] Horii R, Akiyama F, Ito Y, et al: Histological features of breast cancer, highly sensi‐
tive to chemotherapy. Breast Cancer 14:393-400, 2007
[16] Rouzier R, Pusztai L, Delaloge S, et al: Nomograms to predict pathologic complete
response and metastasis-free survival after preoperative chemotherapy for breast
cancer. J Clin Oncol 23:8331-9, 2005
[17] Wang J, Buchholz TA, Middleton LP, et al: Assessment of histologic features and ex‐
pression of biomarkers in predicting pathologic response to anthracycline-based neo‐
adjuvant chemotherapy in patients with breast carcinoma. Cancer 94:3107-14, 2002
[18] Sanchez-Rovira P, Anton A, Barnadas A, et al: Classical markers like ER and ki-67,
but also survivin and pERK, could be involved in the pathological response to gemci‐
tabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients:
results from the GEICAM/2002-01 phase II study. Clin Transl Oncol 14:430-6, 2012
[19] Esserman LJ, Berry DA, Cheang MC, et al: Chemotherapy response and recurrence-
free survival in neoadjuvant breast cancer depends on biomarker profiles: results
from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res
Treat 132:1049-62, 2012
[20] al. Ae: Role of proliferation in response to neoadjuvant chemotherapy in GEICAM/
2006-03 and GEICAM/2006-14 breast cancer patients. J Clin Oncol, 2012
[21] Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond
differently to preoperative chemotherapy. Clin Cancer Res 11:5678-85, 2005
[22] Li XR, Liu M, Zhang YJ, et al: CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein
expressions as predictors of pathological complete response to neoadjuvant chemo‐
therapy in triple-negative breast cancer patients. Med Oncol 28 Suppl 1:S129-34, 2011
[23] Keam B, Im SA, Kim HJ, et al: Prognostic impact of clinicopathologic parameters in
stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemo‐
therapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7:203,
2007
[24] Li XR, Liu M, Zhang YJ, et al: ER, PgR, HER-2, Ki-67, topoisomerase IIalpha, and
nm23-H1 proteins expression as predictors of pathological complete response to neo‐
Neoadjuvant Chemotherapy: Role in Breast Cancer
http://dx.doi.org/10.5772/53192
73
adjuvant chemotherapy for locally advanced breast cancer. Med Oncol 28 Suppl
1:S48-54, 2011
[25] Keskin S, Muslumanoglu M, Saip P, et al: Clinical and pathological features of breast
cancer associated with the pathological complete response to anthracycline-based ne‐
oadjuvant chemotherapy. Oncology 81:30-8, 2011
[26] Dejeux E, Ronneberg JA, Solvang H, et al: DNA methylation profiling in doxorubicin
treated primary locally advanced breast tumours identifies novel genes associated
with survival and treatment response. Mol Cancer 9:68, 2010
[27] Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete
pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cy‐
clophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-93, 2004
[28] Zembutsu H, Suzuki Y, Sasaki A, et al: Predicting response to docetaxel neoadjuvant
chemotherapy for advanced breast cancers through genome-wide gene expression
profiling. Int J Oncol 34:361-70, 2009
[29] van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clini‐
cal outcome of breast cancer. Nature 415:530-6, 2002
[30] Seredina TA, Goreva OB, Talaban VO, et al: Association of cytochrome P450 genetic
polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
BMC Med Genet 13:45, 2012
[31] Huober J, von Minckwitz G, Denkert C, et al: Effect of neoadjuvant anthracycline-
taxane-based chemotherapy in different biological breast cancer phenotypes: overall
results from the GeparTrio study. Breast Cancer Res Treat 124:133-40, 2010
[32] Iwase S, Yamamoto D, Kuroda Y, et al: Phase II trial of preoperative chemotherapy
for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial. Anticanc‐
er Res 31:1483-7, 2011
[33] Symmans WF, Volm MD, Shapiro RL, et al: Paclitaxel-induced apoptosis and mitotic
arrest assessed by serial fine-needle aspiration: implications for early prediction of
breast cancer response to neoadjuvant treatment. Clin Cancer Res 6:4610-7, 2000
[34] Hiller DJ, Li BD, Chu QD: CXCR4 as a predictive marker for locally advanced breast
cancer post-neoadjuvant therapy. J Surg Res 166:14-8, 2011
[35] Nagao T, Kinoshita T, Hojo T, et al: The differences in the histological types of breast
cancer and the response to neoadjuvant chemotherapy: The relationship between the
outcome and the clinicopathological characteristics. Breast 21:289-95, 2012
[36] Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast
cancer with primary chemotherapy, surgery, and radiation therapy. Cancer
62:2507-16, 1988
Neoadjuvant Chemotherapy - Increasing Relevance in Cancer Management74
[37] van der Hage JA, van de Velde CJ, Julien JP, et al: Preoperative chemotherapy in pri‐
mary operable breast cancer: results from the European Organization for Research
and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-37, 2001
[38] Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel
versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophos‐
phamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol
17:3412-7, 1999
[39] Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding se‐
quential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide:
preliminary results from National Surgical Adjuvant Breast and Bowel Project Proto‐
col B-27. J Clin Oncol 21:4165-74, 2003
[40] Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel fol‐
lowed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and con‐
current trastuzumab in human epidermal growth factor receptor 2-positive operable
breast cancer: an update of the initial randomized study population and data of addi‐
tional patients treated with the same regimen. Clin Cancer Res 13:228-33, 2007
[41] Chang H: Clinical Advantages of Neoadjuvant Docetaxel (T) and Carboplatin (C) ±
Trastuzumab (H) in Locally Advanced Breast Cancer (LABC). Cancer Research 69,
2009
[42] von Minckwitz G, Kummel S, Vogel P, et al: Neoadjuvant vinorelbine-capecitabine
versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast can‐
cer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542-51, 2008
[43] Untch M, Fasching PA, Konecny GE, et al: PREPARE trial: a randomized phase III
trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epiru‐
bicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide fol‐
lowed by paclitaxel +/- darbepoetin alfa in primary breast cancer--results at the time
of surgery. Ann Oncol 22:1988-98, 2011
[44] Ellis GK, Barlow WE, Gralow JR, et al: Phase III comparison of standard doxorubicin
and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide
plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory
and locally advanced breast cancer: SWOG 0012. J Clin Oncol 29:1014-21, 2011
[45] Jones RL, Lakhani SR, Ring AE, et al: Pathological complete response and residual
DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer
94:358-62, 2006
[46] Mazouni C, Peintinger F, Wan-Kau S, et al: Residual ductal carcinoma in situ in pa‐
tients with complete eradication of invasive breast cancer after neoadjuvant chemo‐
therapy does not adversely affect patient outcome. J Clin Oncol 25:2650-5, 2007
Neoadjuvant Chemotherapy: Role in Breast Cancer
http://dx.doi.org/10.5772/53192
75
[47] von Minckwitz G, Untch M, Blohmer JU, et al: Definition and impact of pathologic
complete response on prognosis after neoadjuvant chemotherapy in various intrinsic
breast cancer subtypes. J Clin Oncol 30:1796-804, 2012
[48] Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Ari‐
midex) on tumor volume in postmenopausal women with breast cancer: a random‐
ized, double-blind, single-center study. Clin Cancer Res 6:2229-35, 2000
[49] Anderson TJ, Dixon JM, Stuart M, et al: Effect of neoadjuvant treatment with anastro‐
zole on tumour histology in postmenopausal women with large operable breast can‐
cer. Br J Cancer 87:334-8, 2002
[50] Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changes during neoadjuvant anas‐
trozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in
breast cancer--a study from the IMPACT trialists. J Clin Oncol 23:2477-92, 2005
[51] Ellis MJ, Suman VJ, Hoog J, et al: Randomized phase II neoadjuvant comparison be‐
tween letrozole, anastrozole, and exemestane for postmenopausal women with estro‐
gen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and
predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J
Clin Oncol 29:2342-9, 2011
[52] Mohammadianpanah M, Ashouri Y, Hoseini S, et al: The efficacy and safety of neo‐
adjuvant chemotherapy +/- letrozole in postmenopausal women with locally ad‐
vanced breast cancer: a randomized phase III clinical trial. Breast Cancer Res Treat
132:853-61, 2012
[53] Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant
everolimus plus letrozole compared with placebo plus letrozole in patients with es‐
trogen receptor-positive breast cancer. J Clin Oncol 27:2630-7, 2009
[54] Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete
remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubi‐
cin chemotherapy: results of a randomized trial in human epidermal growth factor
receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-85, 2005
[55] Semiglazov V, Eiermann W, Zambetti M, et al: Surgery following neoadjuvant thera‐
py in patients with HER2-positive locally advanced or inflammatory breast cancer
participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol
37:856-63, 2011
[56] Untch M, Loibl S, Bischoff J, et al: Lapatinib versus trastuzumab in combination with
neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a
randomised phase 3 trial. Lancet Oncol 13:135-44, 2012
[57] Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-posi‐
tive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3
trial. Lancet 379:633-40, 2012
Neoadjuvant Chemotherapy - Increasing Relevance in Cancer Management76
[58] al Re: Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ op‐
erable breast cancer: NSABP protocol B-41. J Clin Oncol, 2012
[59] Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab
and trastuzumab in women with locally advanced, inflammatory, or early HER2-
positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2
trial. Lancet Oncol 13:25-32, 2012
[60] Pierga JY, Petit T, Delozier T, et al: Neoadjuvant bevacizumab, trastuzumab, and che‐
motherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an
open-label, single-arm phase 2 study. Lancet Oncol 13:375-84, 2012
[61] Bear HD, Tang G, Rastogi P, et al: Bevacizumab added to neoadjuvant chemotherapy
for breast cancer. N Engl J Med 366:310-20, 2012
[62] von Minckwitz G, Eidtmann H, Rezai M, et al: Neoadjuvant chemotherapy and beva‐
cizumab for HER2-negative breast cancer. N Engl J Med 366:299-309, 2012
[63] al. Ee: ARTemis: Randomized trial with neoadjuvant chemotherapy for patients with
early breast cancer. J Clin Oncol, 2012
[64] Rastogi P, Buyse ME, Swain SM, et al: Concurrent bevacizumab with a sequential
regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecita‐
bine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II tri‐
al of the NSABP Foundation Research Group. Clin Breast Cancer 11:228-34, 2011
[65] Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant Cisplatin in tri‐
ple-negative breast cancer. J Clin Oncol 28:1145-53, 2010
[66] Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young
women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin
Oncol 28:375-9, 2010
[67] al. Te: Results of the East Carolina Breast Center phase II trial of neoadjuvant metro‐
nomic chemotherapy in triple-negative breast cancer (NCT00542191). J Clin Oncol,
2012
[68] al. Ke: A multicenter phase II neoadjuvant trial of bevacizumab combined with doce‐
taxel plus carboplatin in the treatment of triple-negative breast cancer: Korean Can‐
cer Study Group (KCSG-BR 0905, NCT 01208480). J Clin Oncol, 2012
[69] al. EAe: Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in
patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized
phase II study. J Clin Oncol 29, 2011
[70] al. Be: Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients
with triple-negative breast cancer. J Clin Oncol, 2012
Neoadjuvant Chemotherapy: Role in Breast Cancer
http://dx.doi.org/10.5772/53192
77
[71] al. Se: Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin fol‐
lowed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer.
J Clin Oncol, 2012
[72] Roche H, Yelle L, Cognetti F, et al: Phase II clinical trial of ixabepilone (BMS-247550),
an epothilone B analog, as first-line therapy in patients with metastatic breast cancer
previously treated with anthracycline chemotherapy. J Clin Oncol 25:3415-20, 2007
[73] Low JA, Wedam SB, Lee JJ, et al: Phase II clinical trial of ixabepilone (BMS-247550),
an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin On‐
col 23:2726-34, 2005
[74] Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in
a phase II study of patients with advanced breast cancer resistant to an anthracycline,
a taxane, and capecitabine. J Clin Oncol 25:3407-14, 2007
[75] Thomas E, Tabernero J, Fornier M, et al: Phase II clinical trial of ixabepilone
(BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic
breast cancer. J Clin Oncol 25:3399-406, 2007
[76] Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic
breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol
25:5210-7, 2007
[77] Baselga J, Zambetti M, Llombart-Cussac A, et al: Phase II genomics study of ixabepi‐
lone as neoadjuvant treatment for breast cancer. J Clin Oncol 27:526-34, 2009
[78] Perez EA, Patel T, Moreno-Aspitia A: Efficacy of ixabepilone in ER/PR/HER2-nega‐
tive (triple-negative) breast cancer. Breast Cancer Res Treat 121:261-71, 2010
[79] Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 144:646-74,
2011
[80] Harper JW, Elledge SJ: The DNA damage response: ten years after. Mol Cell
28:739-45, 2007
[81] Ossovskaya V, Koo IC, Kaldjian EP, et al: Upregulation of Poly (ADP-Ribose) Poly‐
merase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tu‐
mor Types. Genes Cancer 1:812-21, 2010
[82] Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mu‐
tant cells as a therapeutic strategy. Nature 434:917-21, 2005
[83] Adams S, Chakravarthy AB, Donach M, et al: Preoperative concurrent paclitaxel-ra‐
diation in locally advanced breast cancer: pathologic response correlates with five-
year overall survival. Breast Cancer Res Treat 124:723-32, 2010
[84] Martincich L, Montemurro F, De Rosa G, et al: Monitoring response to primary che‐
motherapy in breast cancer using dynamic contrast-enhanced magnetic resonance
imaging. Breast Cancer Res Treat 83:67-76, 2004
Neoadjuvant Chemotherapy - Increasing Relevance in Cancer Management78
[85] Hylton NM, Blume JD, Bernreuter WK, et al: Locally Advanced Breast Cancer: MR
Imaging for Prediction of Response to Neoadjuvant Chemotherapy--Results from
ACRIN 6657/I-SPY TRIAL. Radiology 263:663-672, 2012
[86] Loo CE, Straver ME, Rodenhuis S, et al: Magnetic resonance imaging response moni‐
toring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer
subtype. J Clin Oncol 29:660-6, 2011
[87] Inokuchi M, Furukawa H, Kayahara M, et al: [The role of / 18FDG PET/CT for the
initial staging and therapy in primary breast cancer]. Gan To Kagaku Ryoho
36:2526-31, 2009
[88] Schelling M, Avril N, Nahrig J, et al: Positron emission tomography using [(18)F]Flu‐
orodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin On‐
col 18:1689-95, 2000
[89] Avril N, Sassen S, Schmalfeldt B, et al: Prediction of response to neoadjuvant chemo‐
therapy by sequential F-18-fluorodeoxyglucose positron emission tomography in pa‐
tients with advanced-stage ovarian cancer. J Clin Oncol 23:7445-53, 2005
[90] Choi JH, Lim HI, Lee SK, et al: The role of PET CT to evaluate the response to neoad‐
juvant chemotherapy in advanced breast cancer: comparison with ultrasonography
and magnetic resonance imaging. J Surg Oncol 102:392-7, 2010
[91] Tateishi U, Miyake M, Nagaoka T, et al: Neoadjuvant chemotherapy in breast cancer:
prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR
imaging--prospective assessment. Radiology 263:53-63, 2012
Neoadjuvant Chemotherapy: Role in Breast Cancer
http://dx.doi.org/10.5772/53192
79

